Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (Cancelled).

3. (Withdrawn) A method for intranasal administration of calcitonin which comprises administering intranasally to an individual a solution of calcitonin consisting essentially of calcitonin, chlorobutanol at a concentration of 0.25% weight/weight, and water and having a pH of about 3.5, sodium chloride at a concentration of about 0.85%, and optionally hydrochloric acid in an amount sufficient to adjust the pH of the solution to about 3.5, and wherein the aqueous solution has an oxygen at a content of less than about 5%.

4. (Withdrawn) The method of claim 3 wherein the calcitonin is present in solution at a concentration of about 0.0355 weight/weight.

5. (Withdrawn) The method of claim 3 wherein the calcitonin formulation is administered into a nose of an individual through an actuator tip as a spray, wherein the spray has a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

6. (Withdrawn) The method of claim 5 wherein the spray produces droplets, wherein less that 5% of the droplets are less than 10 microns in size.

7. (Withdrawn) The method of claim 5 wherein the spray has a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

8. (Previously Presented) A composition consisting of:
an aqueous solution of calcitonin at a concentration of about 0.0355% weight/weight;
chlorobutanol at a concentration of between about 0.25% and about 0.4% weight/weight;
sodium chloride at a concentration of about 0.85% weight/weight;
wherein the solution has a pH between about 3 to 4 and less than about 5% oxygen;
wherein the composition is suitable for intranasal administration in humans.

9-11. (Cancelled)

12. (Previously Presented) A composition consisting of:
an aqueous solution of salmon calcitonin at a concentration of 2200 International Units (I.U.) per ml;
chlorobutanol at a concentration of between 0.25% and about 0.4% weight/weight;
sodium chloride at a concentration of 0.85% weight/weight;
wherein the solution has a pH between about 3 to 4 and less than about 5% oxygen; and
wherein the composition is suitable for intranasal administration in humans.

13-15. (Cancelled)

16. (Previously Presented) A pharmaceutical composition consisting of:
an aqueous solution of salmon calcitonin at a concentration of 2200 International Units (I.U.) per ml;
chlorobutanol at a concentration of between 0.25% and about 0.4% weight/weight;
sodium chloride at a concentration of 0.85% weight/weight;
wherein the solution has a pH between about 3 to 4 and less than about 5% oxygen; and
wherein the composition is suitable for intranasal administration in humans.

17-19. (Cancelled)

20. (Previously Presented) A pharmaceutical device comprising a composition according to claim 8 and an actuator to produce an aerosol spray of the composition, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

21. (Previously Presented) A pharmaceutical device comprising a composition according to claim 8 and an actuator to produce an aerosol spray of the composition, wherein the spray has a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

22. (Previously Presented) A pharmaceutical device comprising a composition according to claim 8 and an actuator to produce an aerosol spray of the composition, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0

cm from the actuator tip, wherein less than 5% of the droplets are smaller than 10 microns in size.

23. (Previously Presented) A pharmaceutical device comprising a composition according to claim 12 and an actuator to produce an aerosol spray of the composition, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

24. (Previously Presented) A pharmaceutical device comprising a composition according to claim 12 and an actuator to produce an aerosol spray of the composition, wherein the spray has a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

25. (Previously Presented) A pharmaceutical device comprising a composition according to claim 12 and an actuator to produce an aerosol spray of the composition, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip, wherein less than 5% of the droplets are smaller than 10 microns in size.

26. (Previously Presented) A pharmaceutical device comprising a composition according to claim 16 and an actuator to produce an aerosol spray of the composition, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

27. (Previously Presented) A pharmaceutical device comprising a composition according to claim 16 and an actuator to produce an aerosol spray of the composition, wherein the spray has a spray pattern major axis of about 31.2 mm and a minor axis of about 27.4 mm.

28. (Previously Presented) A pharmaceutical device comprising a composition according to claim 16 and an actuator to produce an aerosol spray of the composition, the spray having a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip, wherein less than 5% of the droplets are smaller than 10 microns in size.

29. (Previously Presented) A composition consisting of a solution of (i) calcitonin; (ii) chlorobutanol at a concentration of equal to or greater than about 0.25% and less than about

0.4% weight/weight; (iii) water; (iv) sodium chloride; and optionally (v) hydrochloric acid; wherein the composition has a pH of 4 or less; and wherein the composition is suitable for intranasal administration in humans.

30. (Previously Presented) A composition consisting of a solution of calcitonin, chlorobutanol at a concentration of about 0.25% weight/weight, water, sodium chloride, and optionally hydrochloric acid, wherein the composition has a pH of 4 or less, and wherein the composition is suitable for intranasal administration in humans.